PMID- 36522857
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20230112
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Jan
TI  - An evaluation of mavacamten for the treatment of symptomatic obstructive 
      hypertrophic cardiomyopathy in adults.
PG  - 5-13
LID - 10.1080/14779072.2023.2159811 [doi]
AB  - INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder 
      leading to hypertrophy of the left ventricle excluding other etiologies. Patients 
      can experience exertional chest pain, dyspnea, syncope or even sudden cardiac 
      death (SCD). Traditional medical management consists of beta blockers (BB), 
      nondihydropyridine calcium channel blockers and disopyramide. Mavacamten, a novel 
      cardiac myosin inhibitor, has recently been shown to improve both quantitative 
      and qualitative measures of obstructive HCM allowing some patients to defer 
      septal reduction therapy. AREAS COVERED: This review delves into the 
      pharmacotherapy of mavacamten, the evidence behind this first-in-class drug for 
      HCM, guidance for clinical usage, and possible future uses for cardiac myosin 
      inhibitors. EXPERT OPINION: Mavacamten should be incorporated into the standard 
      armamentarium of medications used to treat obstructive HCM. PIONEER-HCM, 
      EXPLORER-HCM and VALOR-HCM demonstrated improvements in peak LVOT gradient both 
      at rest and post-exercise, cardiac biomarkers, New York Heart Association (NYHA) 
      functional class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. 
      Unlike other medications utilized for treatment, mavacamten can delay or even 
      obviate the need for septal reduction therapy.
FAU - Dong, Tiffany
AU  - Dong T
AUID- ORCID: 0000-0002-0086-9289
AD  - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, 
      Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Nissen, Steven
AU  - Nissen S
AD  - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, 
      Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Ospina, Susan
AU  - Ospina S
AD  - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, 
      Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Desai, Milind Y
AU  - Desai MY
AD  - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, 
      Cleveland Clinic, Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221222
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (MYK-461)
RN  - 0 (Benzylamines)
RN  - EC 3.6.1.- (Cardiac Myosins)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *Cardiomyopathy, Hypertrophic/drug therapy
MH  - Heart
MH  - Benzylamines/therapeutic use
MH  - Cardiac Myosins/therapeutic use
OTO - NOTNLM
OT  - EXPLORER HCM
OT  - Mavacamten
OT  - VALOR HCM
OT  - hypertrophic cardiomyopathy
OT  - septal reduction therapy
EDAT- 2022/12/17 06:00
MHDA- 2023/01/13 06:00
CRDT- 2022/12/16 01:02
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2023/01/13 06:00 [medline]
PHST- 2022/12/16 01:02 [entrez]
AID - 10.1080/14779072.2023.2159811 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2023 Jan;21(1):5-13. doi: 
      10.1080/14779072.2023.2159811. Epub 2022 Dec 22.